Medicare Enrolled
Dr. Raul Storey-Rojas, M.D.
Hematology & Oncology · Vero Beach, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Storey-Rojas from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Storey-Rojas? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Storey-Rojas
Dr. Raul Storey-Rojas is a hematology & oncology in Vero Beach, FL, with 18 years in practice. Based on federal Medicare data, Dr. Storey-Rojas performed 269,118 Medicare services across 9,452 unique beneficiaries.
Between the years covered by Open Payments, Dr. Storey-Rojas received a total of $26,580 from 96 pharmaceutical and/or device companies across 1404 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Storey-Rojas is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 1% volume in FL$ $26,580 industry payments
Medicare Practice Summary
Medicare Utilization ↗269,118
Medicare services
Top 1% in FL for hematology & oncology
9,452
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~14,951 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 96,390 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 37,800 | $43 | $137 |
| Nivolumab injection (Opdivo) | 22,640 | $24 | $72 |
| Anti-nausea injection (aprepitant) | 14,560 | $1 | $5 |
| Oxaliplatin chemotherapy injection | 11,600 | $0 | $12 |
| Iron sucrose injection (Venofer) | 9,000 | $0 | $5 |
| Daratumumab injection (Darzalex) | 8,640 | $38 | $110 |
| Denosumab injection (Prolia/Xgeva) | 8,580 | $18 | $51 |
| Epoetin alfa injection (Procrit) for anemia | 7,951 | $6 | $23 |
| Paclitaxel chemotherapy injection | 7,950 | $0 | $2 |
| Complete blood count (CBC) with differential | 3,768 | $8 | $29 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,432 | $26 | $116 |
| Blood draw (venipuncture) | 3,359 | $8 | $9 |
| Dexamethasone injection (steroid) | 3,086 | $0 | $3 |
| Epoetin alfa injection (Retacrit) for anemia | 2,910 | $6 | $22 |
| Iron infusion (Monoferric) | 2,600 | $16 | $57 |
| Immune globulin infusion (Gammagard) | 2,204 | $36 | $108 |
| Injection, docetaxel, 1 mg | 1,916 | $0 | $7 |
| Office visit, established patient (30-39 min) | 1,857 | $97 | $339 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,810 | $1 | $28 |
| Contrast dye for imaging (iodine-based) | 1,660 | $0 | $1 |
| Injection, bortezomib, 0.1 mg | 1,554 | $4 | $113 |
| Injection, atropine sulfate, 0.01 mg | 1,280 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,279 | $23 | $185 |
| Drug injection, under skin or into muscle | 1,019 | $11 | $69 |
| Injection, leucovorin calcium, per 50 mg | 836 | $3 | $12 |
| Anti-nausea injection (ondansetron/Zofran) | 748 | $0 | $9 |
| Administration of chemotherapy into vein, 1 hour or less | 632 | $102 | $378 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 625 | $3 | $205 |
| Red blood count, automated test | 601 | $4 | $10 |
| Injection of additional new drug or substance into vein | 567 | $12 | $61 |
| Automated urinalysis | 560 | $2 | $8 |
| Injection, fluorouracil, 500 mg | 485 | $2 | $7 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 453 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 303 | $50 | $189 |
| Office visit, established patient (20-29 min) | 295 | $66 | $239 |
| Complete ultrasound scan behind abdominal cavity | 286 | $82 | $297 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 244 | $23 | $84 |
| Injection, diphenhydramine hcl, up to 50 mg | 234 | $1 | $3 |
| Injection, carboplatin, 50 mg | 230 | $2 | $41 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 219 | $134 | $562 |
| Administration of chemotherapy into vein, each additional hour | 210 | $22 | $79 |
| Infusion, normal saline solution , 1000 cc | 207 | $2 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 173 | $51 | $178 |
| Infusion into a vein for hydration, 31-60 minutes | 169 | $25 | $156 |
| Injection, zoledronic acid, 1 mg | 148 | $7 | $69 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 138 | $26 | $89 |
| Bladder ultrasound after voiding | 128 | $8 | $51 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 128 | $17 | $59 |
| New patient office visit (45-59 min) | 121 | $127 | $453 |
| New patient office visit, complex (60-74 min) | 113 | $168 | $585 |
| Electronic assessment of bladder emptying | 112 | $9 | $135 |
| Injection of drug or substance into vein | 107 | $29 | $156 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 97 | $16 | $56 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 97 | $56 | $206 |
| Ultrasound scan of pelvic region through rectum | 91 | $98 | $344 |
| Initial hospital admission, high complexity | 86 | $140 | $556 |
| Drawing of blood for a medical problem | 84 | $70 | $277 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 76 | $1 | $7 |
| Limited ultrasound scan of pelvis | 71 | $27 | $128 |
| Administration of additional new drug or substance into vein using push technique | 69 | $45 | $170 |
| Injection, magnesium sulfate, per 500 mg | 65 | $1 | $2 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 54 | $137 | $637 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 46 | $16 | $56 |
| Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg | 45 | $307 | $1,210 |
| Infusion into a vein for hydration, each additional hour | 43 | $10 | $42 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 33 | $30 | $517 |
| Insertion of lower leg neurostimulator electrode | 33 | $95 | $335 |
| Hospital follow-up visit, moderate complexity | 33 | $64 | $197 |
| Office visit, established patient, complex (40-54 min) | 31 | $144 | $474 |
| Biofeedback training for bowel or bladder control, initial 15 minutes | 30 | $60 | $209 |
| Insertion of device into abdomen with pressure and urine flow rate study | 29 | $155 | $295 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 18 | $313 | $894 |
| Ct scan of abdomen and pelvis before and after contrast | 18 | $208 | $708 |
| Hospital follow-up visit, low complexity | 16 | $41 | $109 |
| Ultrasound scan of scrotum | 13 | $47 | $177 |
| Initial hospital admission, moderate complexity | 12 | $87 | $377 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 11 | $269 | $827 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
38.1% high complexity
57.6% medium
4.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$26,580
Total received (2018-2024)
Avg $3,797/year across 7 years
Top 21% in FL for hematology & oncology
96
Companies
1,404
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$26,358 (99.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$222 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,862
2023$4,481
2022$3,914
2021$3,263
2020$3,219
2019$3,564
2018$4,277
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$2,304
AstraZeneca Pharmaceuticals LP
$1,896
Janssen Biotech, Inc.
$1,832
Novartis Pharmaceuticals Corporation
$1,693
PFIZER INC.
$1,651
Celgene Corporation
$1,542
Amgen Inc.
$1,194
Incyte Corporation
$1,016
Lilly USA, LLC
$888
Merck Sharp & Dohme Corporation
$707
GENZYME CORPORATION
$699
Seagen Inc.
$680
Merck Sharp & Dohme LLC
$673
GlaxoSmithKline, LLC.
$643
Pharmacyclics LLC, An AbbVie Company
$624
Genentech USA, Inc.
$588
Bayer HealthCare Pharmaceuticals Inc.
$508
Daiichi Sankyo Inc.
$489
Astellas Pharma US Inc
$470
Gilead Sciences, Inc.
$361
Ipsen Biopharmaceuticals, Inc
$329
Eisai Inc.
$312
Foundation Medicine, Inc.
$307
TESARO, Inc.
$220
Alexion Pharmaceuticals, Inc.
$219
Takeda Pharmaceuticals U.S.A., Inc.
$213
Kite Pharma, Inc.
$212
Regeneron Healthcare Solutions, Inc.
$207
BeiGene USA, Inc.
$192
ARRAY BIOPHARMA INC
$170
Boehringer Ingelheim Pharmaceuticals, Inc.
$143
EISAI INC.
$142
Dova Pharmaceuticals
$142
Pharmacyclics LLC, an AbbVie Company
$140
Axonics, Inc.
$137
AbbVie Inc.
$125
Karyopharm Therapeutics Inc.
$115
Bayer Healthcare Pharmaceuticals Inc.
$114
Puma Biotechnology, Inc.
$111
Boston Scientific Corporation
$109
ABBVIE INC.
$102
Kyowa Kirin, Inc.
$96
Stemline Therapeutics Inc.
$96
SERVIER PHARMACEUTICALS LLC
$95
Lexicon Pharmaceuticals, Inc.
$92
Taiho Oncology, Inc.
$91
Exelixis Inc.
$88
Deciphera Pharmaceuticals Inc.
$88
MorphoSys, US Inc.
$84
Seattle Genetics, Inc.
$82
PharmaEssentia USA Corporation
$81
TerSera Therapeutics LLC
$71
Clovis Oncology, Inc.
$68
Janssen Products, LP
$65
Myriad Genetic Laboratories, Inc.
$64
Heron Therapeutics, Inc.
$60
EMD Serono, Inc.
$55
JAZZ PHARMACEUTICALS INC.
$52
Blueprint Medicines Corporation
$51
G1 Therapeutics, Inc.
$48
SOBI, INC
$47
Adaptive Biotechnologies Corporation
$47
Sirtex Medical Inc
$46
Biocon Biologics Inc
$46
Aveo Pharmaceuticals, Inc.
$45
CSL Behring
$41
Shire North American Group Inc
$37
Advanced Accelerator Applications
$36
Global Blood Therapeutics, Inc.
$36
Agios Pharmaceuticals, Inc.
$34
Octapharma USA, Inc.
$32
Dendreon Pharmaceuticals LLC
$31
Epizyme, Inc.,
$30
TAIHO ONCOLOGY, INC.
$29
PUMA BIOTECHNOLOGY, INC.
$29
AMAG Pharmaceuticals, Inc.
$26
CTI BioPharma Corp.
$23
Servier Pharmaceuticals LLC
$23
Janssen Pharmaceuticals, Inc
$23
Helsinn Therapeutics (U.S.), Inc.
$22
Secura Bio, Inc.
$21
Acrotech Biopharma LLC
$20
Acceleron Pharma, Inc.
$19
NOVARTIS PHARMACEUTICALS CORPORATION
$18
Sun Pharmaceutical Industries Inc.
$18
Array BioPharma Inc.
$16
SpringWorks Therapeutics, Inc.
$16
Alnylam Pharmaceuticals Inc.
$16
Partner Therapeutics, Inc.
$16
Jazz Pharmaceuticals Inc.
$16
Pharmacosmos Therapeutics Inc.
$15
Progenics Pharmaceuticals, Inc.
$15
Clinigen Inc
$13
Sysmex Inostics Inc
$12
AbbVie, Inc.
$12
Fortovia Therapeutics, Inc.
$10
Top 3 companies account for 22.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · AMS · AYVAKIT · Abraxane · Afstyla · Alecensa · Aliqopa · Avastin · Axonics · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · CINVANTI · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EVENITY · Enhertu · Erleada · FARYDAK · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · Farydak · Fulphila · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · HYQVIA · Halaven · Herceptin · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Idelvion · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kadcyla · Kyprolis · LEUKINE · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MONJUVI · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Ogivri · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYLARIFY · PYRUKYND · Padcev · Perjeta · Pomalyst · Poteligeo · Proleukin · Prolia · QINLOCK · REBLOZYL · RETEVMO · RYBREVANT · Reblozyl · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · Soltamox · Somatuline Depot · Stivarga · TAGRISSO · TALVEY · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEVIMBRA · TIBSOVO · TIVDAK · TUKYSA · Tazverik · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONVENDI · VOTRIENT · Vectibix · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $10 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
19
Per 100K population
11.6
County median income
$71,049
Nearest hospital
CLEVELAND CLINIC INDIAN RIVER HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Storey-Rojas is a mixed practice specialist, with above-average Medicare volume (top 1% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Storey-Rojas experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Storey-Rojas performed 96,390 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Storey-Rojas receive payments from pharmaceutical companies?
Yes. Dr. Storey-Rojas received a total of $26,580 from 96 companies across 1,404 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Storey-Rojas's costs compare to other hematology & oncologys in Vero Beach?
Dr. Storey-Rojas's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Storey-Rojas) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Vero Beach
Browse hematology & oncologys in Vero Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology